Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные международные и национальные рекомендации по применению инновационных сахароснижающих препаратов – инкретинов – в лечении сахарного диабета типа 2
Современные международные и национальные рекомендации по применению инновационных сахароснижающих препаратов – инкретинов – в лечении сахарного диабета типа 2
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31 (12): 1–11.
2. Canadian Diabetes Association. 2008 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32 (1): S1–S201.
3. NICE clinical guideline 66. Type 2 diabetes: the management of type 2 diabetes. May 2008. www.nice.org.uk/CG66
4. NICE short clinical guideline 87. Type 2 diabetes: newer agents. London: NICE, 2009.
5. Edwards GMB, Winocour PH on behalf of the Association of British Clinical Diabetologists (ABCD). ABCD position statement on incretin mimetics and DPP-4 inhibitors 2009. Pract Diab Int 2009; 5 (26): 191–5.
6. AACE/ACE Consensus statement on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009; 6 (15): 540–59.
7. Консенсус РАЭ. Сахаоный диабет, 2011; 4, в печати.
8. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolosm 2011; 13: 7–18.
9. Nowicki M et al. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment compared with placebo. Diabetes Obes Metab 2011; 13 (6): 523–32.
10. Patel C, Castaneda L, Frevert U et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract no. 537-P]. Diabetes 2008; 57 (Suppl. 1): A160.
2. Canadian Diabetes Association. 2008 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32 (1): S1–S201.
3. NICE clinical guideline 66. Type 2 diabetes: the management of type 2 diabetes. May 2008. www.nice.org.uk/CG66
4. NICE short clinical guideline 87. Type 2 diabetes: newer agents. London: NICE, 2009.
5. Edwards GMB, Winocour PH on behalf of the Association of British Clinical Diabetologists (ABCD). ABCD position statement on incretin mimetics and DPP-4 inhibitors 2009. Pract Diab Int 2009; 5 (26): 191–5.
6. AACE/ACE Consensus statement on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009; 6 (15): 540–59.
7. Консенсус РАЭ. Сахаоный диабет, 2011; 4, в печати.
8. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolosm 2011; 13: 7–18.
9. Nowicki M et al. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment compared with placebo. Diabetes Obes Metab 2011; 13 (6): 523–32.
10. Patel C, Castaneda L, Frevert U et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract no. 537-P]. Diabetes 2008; 57 (Suppl. 1): A160.
Авторы
М.В.Шестакова
ФГБУ Эндокринологический научный центр Минздравсоцразвития РФ
ФГБУ Эндокринологический научный центр Минздравсоцразвития РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.